Peer-influenced content. Sources you trust. No registration required. This is HCN.
Neuro-Oncology
Long-term follow-up data demonstrate a significant overall survival advantage with combination therapy, showing a hazard ratio of 0.54 (95% CI 0.31-0.95) for radiation plus temozolomide versus radiation alone in grade II gliomas.
Neurology February 20th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS